Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
=== Hong Kong === 7-Eleven ÆON (Formerly JUSCO, also considered a department store) c!ty'super Subsidiaries of China Resources, including: CR Vanguard (Defunct) U Select DCH Food Mart (Defunct) Marks & Spencer Seibu Department Stores (Defunct) Yata (also considered a department store) Sogo (also considered a department store) UNY/APiTA Subsidiaries of AS Watson, including: PARKnSHOP Fusion Taste International by PARKnSHOP Gourmet Great Food le Parc Subsidiaries of DFI Retail Group, including: Wellcome Market Place/Market Place by Jasons 3hreeSixty Oliver's The Delicatessen Kai Bo DS Groceries
== Function == The Gβγ complex is an essential element in the GPCR signaling cascade. It has two main states for which it performs different functions. When Gβγ is interacting with Gα it functions as a negative regulator. In the heterotrimer form, the Gβγ dimer increases the affinity of Gα for GDP, which causes the G protein to be in an inactive state. For the Gα subunit to become active, the nucleotide exchange must be induced by the GPCR. Studies have shown that it is the Gβγ dimer that demonstrates specificity for the appropriate receptor and that the Gγ subunit actually enhances the interaction of the Gα subunit with the GPCR. The GPCR is activated by an extracellular ligand and subsequently activates the G protein heterotrimer by causing a conformational change in the Gα subunit. This causes the replacement of GDP with GTP as well as the physical dissociation of the Gα and the Gβγ complex.
diffusion The net movement of atoms or molecules from a region of higher concentration to a region of lower concentration. Diffusion is driven by a gradient in chemical potential of the diffusing species and depends on the random walk of particles; hence it results in mixing or mass transport without required directed bulk motion.
=== King's Police Medal (KPM) === Bernard Kenneth Bonamy Jr., Assistant Commissioner of Police, Royal Bahamas Police Force. Theophilus Andrew Cunningham. Assistant Commissioner of Police, Royal Bahamas Police Force.
Vernix caseosa, or simply vernix, is the waxy white substance found coating the skin of newborn human babies. It is produced by dedicated cells and is thought to have some protective roles during fetal development and for a few hours after birth.
Sources: en.wikipedia.org
== Background == Casey is of Mexican descent. A former Division I soccer player at the University of Texas at El Paso, Casey began training MMA in 2009 after her soccer career was cut short due to an injury. She began her amateur career in 2012, and her professional career a year later.
IDF soldiers have three types of insignia, other than rank insignia, which identify their corps, specific unit, and position. A pin attached to the beret identifies a soldier's corps. Soldiers serving in staffs above corps level are often identified by the General Corps pin, despite not officially belonging to it, or the pin of a related corps. New recruits undergoing tironut (basic training) do not have a pin. Beret colors are also often indicative of the soldier's corps. Most non-combat corps do not have their own beret, and sometimes wear the color of the corps to which the post they're stationed in belongs. Individual units are identified by a shoulder tag attached to the left shoulder strap. Most units in the IDF have their own tags, although those that do not, generally use tags identical to their command's tag (corps, directorate, or regional command). While one cannot always identify the position/job of a soldier, two optional factors help make this identification: an aiguillette attached to the left shoulder strap and shirt pocket, and a pin indicating the soldier's work type, usually given by a professional course. Other pins may indicate the corps or additional courses taken. An optional battle pin indicates a war that a soldier has fought in.
=== Prenatal and newborn screening === Checking for hemoglobinopathies begins during pregnancy, with a prenatal screening questionnaire which includes, among other things, a consideration of health issues in the child's parents and close relatives. During pregnancy, genetic testing can be done on samples taken of fetal blood, of amniotic fluid, or chorionic villus sampling. A routine heel prick test, in which a small sample of blood is collected a few days after birth, can detect some forms of hemoglobinopathy.
Detection of substituted phenethylamines, which include compounds such as 2C-B, MDMA, and other designer drugs, involves various analytical methods aimed at identifying these psychoactive substances. These compounds are structurally similar to amphetamines, making their detection challenging due to potential cross-reactivity in standard drug tests. Techniques like gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), and immunoassay screenings are commonly employed for accurate identification. Advanced methods like high-performance liquid chromatography (HPLC) allow for precise separation and quantification of these substances even at low concentrations. Given the rising use of these drugs in recreational settings, developing sensitive and specific detection techniques remains crucial in forensic toxicology and clinical diagnostics.
Sources: en.wikipedia.org
=== Forensics === These flies are among the most important insect evidence in forensic science, specifically for obtaining time of colonization (TOC) and post mortem interval (PMI). Calliphora species are the most important in temperate regions because of their growth rate in accordance to temperature. By knowing the temperature, the amount of time since the eggs were laid can be estimated. In addition, C. vomitoria has higher threshold temperature for growth than many species; likewise, it is present in many regions. There is a limit to their usage, though, as few species can survive in cold temperatures; most cannot continue development unless it is warmer than roughly 2 °C (36 °F). Degradation of carcasses can be divided into six separate stages: stage of decomposition, fresh stage, bloated stage, active decay stage, advanced decay stage, and remains stage. Adult C. vomitoria first starts to appear at carcasses during the bloated stage, followed by larvae 1 to 3 days after. During the active decay stage, the blowfly larvae population reaches its peak. In buried corpses, information of time since burial and how the body was kept (above/below ground before burial) can also be collected through the identification of C. vomitoria. The study of these flies, however, is limited to areas where entomologists are readily available, as life histories can differ in separate regions. These life histories differ in subtle ways due to differences in climate such as temperature and elevation.
The Registered Cossacks of the Russian Federation are the Cossack paramilitary formation providing public and other services, under the Federal Law of the Russian Federation dated December 5, 2005, No. 154-FZ "On State Service of the Russian Cossacks".
== Production == Selenium is most commonly produced from selenide in many sulfide ores, such as those of copper, nickel, or lead. Electrolytic metal refining is particularly productive of selenium as a byproduct, obtained from the anode mud of copper refineries. Dissolved selenite anions present in the electrolysis solution are also known to interfere with the electrorefining process of copper. Another source was the mud from the lead chambers of sulfuric acid plants, a process that is no longer used. Selenium can be refined from these muds by a number of methods. However, most elemental selenium comes as a byproduct of refining copper or producing sulfuric acid. Since its invention, solvent extraction and electrowinning (SX/EW) production of copper produces an increasing share of the worldwide copper supply. This changes the availability of selenium because only a comparably small part of the selenium in the ore is leached with the copper. Industrial production of selenium usually involves the extraction of selenium dioxide from residues obtained during the purification of copper. Common production from the residue then begins by oxidation with sodium carbonate to produce selenium dioxide, which is mixed with water and acidified to form selenous acid (oxidation step). Selenous acid is bubbled with sulfur dioxide (reduction step) to give elemental selenium. About 2,000 tonnes of selenium were produced in 2011 worldwide, mostly in Germany (650 t), Japan (630 t), Belgium (200 t), and Russia (140 t), and the total reserves were estimated at 93,000 tonnes.
=== Other neurological disorders === Tourette syndrome. The available data was determined to be insufficient to allow reliable conclusions to be drawn regarding the effectiveness of oral cannabis extract or THC in controlling tics. Cervical dystonia. Insufficient data was available to assess the effectiveness of oral cannabis extract of THC in treating cervical dystonia.
Megakaryocyte and platelet production is regulated by thrombopoietin, a hormone produced in the kidneys and liver. Each megakaryocyte produces between 1,000 and 3,000 platelets during its lifetime. An average of 1011 platelets are produced daily in a healthy adult. Reserve platelets are stored in the spleen and are released when needed by splenic contraction induced by the sympathetic nervous system.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.